Impact of primary prophylaxis on febrile neutropenia within community practices in the US

References

• Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003;23: 15–19S.
   Google Scholar
• Crawford J, Dale D, Lyman G. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–237.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557–571.
   PubMedGoogle Scholar
• Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901–906.
   PubMed Web of Science ®Google Scholar
• Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205–1211.
   PubMed Web of Science ®Google Scholar
• Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8: 963–977.
   PubMed Web of Science ®Google Scholar
• Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993;4:651–656.
   PubMed Web of Science ®Google Scholar
• Crawford J. The importance of chemotherapy dose intensity in lung cancer. Semin Oncol 2004;31:25–31.
   PubMedGoogle Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–170.
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–324.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–1184.
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A:S23–30.
   Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903–909.
   PubMed Web of Science ®Google Scholar
• Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514–519.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25: 3158–3167.
   PubMed Web of Science ®Google Scholar
• Patton J, Fridman M, Perry T, Masaquel A. Trends in chemotherapy and growth factor administration for early stage breast cancer and intermediate grade non-Hodgkin's lymphoma patients. Abstract presented at Multinational Association of Supportive Care in Cancer (MASCC) in Toronto, Canada, 2006.
   Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manage Care Pharm 2007;13:337–348.
   PubMed Web of Science ®Google Scholar
• Fortner B, Stolshek B, Mao Q, Schwartzberg L. Association of IV antibiotic use and hospitalisation with filgrastim (F) and pegfilgrastim (PegF) utilization in a community oncology clinic sample. In: 40th ASHP Midyear Clinical Meeting and Exhibition, 2003, December 7-11, 2003; New Orleans, LA, 2003.
   Google Scholar
• Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manage Care Pharm 2003;9:15–21.
   PubMedGoogle Scholar
• Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol 2000;18:1764–1770.
   PubMed Web of Science ®Google Scholar
• Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915–920.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
   PubMedGoogle Scholar
• United States Department of Health and Human Services. Health Insurance Portability and Accountability Act (HIPAA)
   Google Scholar
• Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11: 550–560.
   PubMed Web of Science ®Google Scholar
• Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564–1571.
   PubMed Web of Science ®Google Scholar
• Smith TC, Khatcheressian J, Lyman G, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:1–19.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network clinical practice guidelines in oncology. Myeloid Growth Factors, version 1.2009 [online].
   Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453
   PubMed Web of Science ®Google Scholar